GLG Pharma uses integrative genomics and a cell culture platform to personalize therapy for diseases like cancer, kidney disease, and psoriasis. They are currently conducting clinical trials for chronic lymphocytic leukemia and triple negative breast cancer. Their STAT3 inhibitors have shown promise in reversing resistance to cancer drugs and are safer alternatives to existing treatments. GLG Pharma also has a line of repurposed drugs and new chemical entities in development.